Valuation: LivaNova PLC

Market Cap 4.53B 23.53B 3.93B 3.68B 3.36B 6.31B 432B 6.41B 43.33B 16.92B 216B 17B 16.63B 722B P/E 2026 *
21.2x
P/E 2027 * 24x
Enterprise Value 4.6B 23.92B 3.99B 3.74B 3.41B 6.42B 439B 6.52B 44.05B 17.2B 220B 17.28B 16.91B 734B EV / Sales 2026 *
3.03x
EV / Sales 2027 * 2.73x
Free-Float
98.6%
Yield 2026 *
-
Yield 2027 * -
1 day+2.64%
Current month+2.64%
1 month+30.88%
3 months+30.88%
6 months+30.01%
Current year+24.71%
1 month 51.9
Extreme 51.9
54.5
Current year 41.64
Extreme 41.64
54.5
1 year 41.64
Extreme 41.64
54.5
3 years 29.88
Extreme 29.88
54.5
5 years 29.88
Extreme 29.88
54.5
10 years 29.88
Extreme 29.88
54.5
Manager TitleAgeSince
Chief Executive Officer 53 2024-02-29
Director of Finance/CFO 56 2020-10-30
Investor Relations Contact - 2022-07-31
Director TitleAgeSince
Director/Board Member 69 2015-10-18
Chairman 74 2021-06-08
Director/Board Member 62 2019-06-17
Change 5-day change 1-year change 3-year change Capi.($)
+2.64%0.00% - - 4.53B
+0.32%+3.07%-14.01%+5.66% 193B
-0.20%+5.42%-2.51%+8.54% 116B
-1.32%-4.62%+6.52%+65.45% 59.16B
+0.32%+3.92%+38.42%+65.14% 55.75B
-0.88%+2.77%-7.14%-35.54% 49.57B
+0.75%+10.19%+14.41%-18.09% 34.52B
+0.23%+3.10% - - 31.22B
-1.74%-0.70%+40.59%-12.31% 24.36B
+1.98%+12.62%-2.80%+25.91% 24.25B
Average +0.21%+4.09%+9.18%+13.10% 65.26B
Weighted average by Cap. -0.02%+3.53%+1.08%+13.53%

Financials

2026 *2027 *
Net sales 1.52B 7.89B 1.32B 1.23B 1.13B 2.12B 145B 2.15B 14.54B 5.68B 72.6B 5.71B 5.58B 242B 1.63B 8.45B 1.41B 1.32B 1.21B 2.27B 155B 2.31B 15.57B 6.08B 77.75B 6.11B 5.98B 259B
Net income 218M 1.13B 189M 178M 162M 305M 20.85B 309M 2.09B 816M 10.44B 820M 802M 34.82B 193M 1B 168M 157M 143M 269M 18.45B 274M 1.85B 722M 9.23B 726M 710M 30.8B
Net Debt 75M 390M 65.01M 60.94M 55.57M 105M 7.16B 106M 718M 280M 3.58B 282M 275M 11.95B -85M -442M -73.68M -69.07M -62.98M -118M -8.11B -120M -813M -317M -4.06B -319M -312M -13.55B
Logo LivaNova PLC
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
Employees
3,300
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
82.20USD
Average target price
89.40USD
Spread / Average Target
+8.76%

Quarterly revenue - Rate of surprise